| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2007;38:2373.)
© 2007 American Heart Association, Inc.
Research Letters |
From the Department of Neurological Surgery (Y.K., T. Kawamata, J.K., T.M., N.M.), Nihon University School of Medicine; the Department of Neurosurgery (J.H.), Tokyo Medical University; the Department of Neurosurgery (H.H.), Nara Medical University; the Department of Neurosurgery (K.K.), Kansai Medical University; the Department of Emergency and Critical Care Medicine (T. Kitahara), Kitasato University School of Medicine; the Department of Neurosurgery (T. Kuroiwa), Osaka Medical College; the Department of Neurosurgery (I.N.), Nagasaki University School of Medicine; the Department of Neurosurgery (A.O.), Iwate Medical University; the Department of Neurosurgery (K.O.), Graduate School of Medicine, Tokyo Medical and Dental University; the Department of Neurosurgery (Y. Seiki), Toho University School of Medicine; the Department of Neurosurgery (Y. Shiokawa), Kyorin University School of Medicine, the Department of Neurosurgery (A.T.), Nippon Medical School; the Division of Neurosurgery (T.T.), Department of Neuroscience and Sensory Organs, Tohoku University Graduate School of Medicine; and the Department of Neurosurgery (T.Y.), Osaka University Medical School, Japan.
Correspondence to Yoichi Katayama, MD, PhD, Department of Neurological Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan. E-mail JDW06164{at}nifty.ne.jp
Abstract
Background and Purpose— Hyponatremia is common after aneurysmal subarachnoid hemorrhage (SAH). It is caused by natriuresis, which induces osmotic diuresis and decreases blood volume, contributing to symptomatic cerebral vasospasm (SCV). Hypervolemic therapy to prevent SCV will not be efficient under this condition. We conducted a randomized controlled trial to assess the efficacy of hydrocortisone, which promotes sodium retention in the kidneys.
Methods— Seventy-one SAH patients were randomly assigned after surgery to treatment with either a placebo (n=36) or 1200 mg/d of hydrocortisone (n=35) for 10 days and tapered thereafter. Both groups underwent hypervolemic therapy. The primary end point was the prevention of hyponatremia.
Results— Hydrocortisone prevented excess sodium excretion (P=0.04) and urine volume (P=0.04). Hydrocortisone maintained the targeted serum sodium level throughout the 14 days (P<0.001), and achieved the management protocol with lower sodium and fluid (P=0.007) supplementation. Hydrocortisone kept the normal plasma osmolarity (P<0.001). SCV occurred in 9 patients (25%) in the placebo group and in 5 (14%) in the hydrocortisone group. No significant difference in the overall outcome was observed between the 2 groups.
Conclusions— Hydrocortisone overcame excess natriuresis and prevented hyponatremia. Although there was no difference in outcome, hydrocortisone supported efficient hypervolemic therapy.
Key Words: hydrocortisone hyponatremia multicenter studies randomized controlled trials subarachnoid hemorrhage
This article has been cited by other articles:
![]() |
G. K. C. Wong and W. S. Poon Risk of High Dose Hydrocortisone in Patients With Aneurysmal Subarachnoid Hemorrhage Stroke, January 1, 2008; 39(1): e12 - e12. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |